FENBENDAZOLE / MEBE...
 

FENBENDAZOLE / MEBENDAZOLE for TNBC  

  RSS

kati1983
(@kati1983)
New Member
Joined: 2 weeks ago
Posts: 1
10/09/2019 3:19 am  

Hi Daniel,

I am 35 y/o, diagnosed 9/2018 with Stage IIB ypT3 N0(i+)(sn) grade 2 triple negative invasive ductal carcinoma. Initial mass was 2.5 x 1.2 x 2.7 cm. Genetic test panel was all negative.
 
I received through a trial Pembro (immunotherapy) + Taxol. By the time I started this treatment on 11/1 an additional mass had formed where they had taken the core biopsy. The Pembro/Taxol combo did not work for me and overall extent of disease grew by the end. I switched to A/C for 5 rounds. First 2 rounds showed dramatic decrease of disease, but additional 3 rounds showed no reduction. I had a partial mastectomy (04/30) + re-incision (05/30). Final surgical sample was 6.6 x 2.4cm with 1 neurotic lymph and 1 lymph w/ trace.  I was supposed to start radiation immediately after, but had issues with the re-incision healing, which took 10 weeks. Four days before I was supposed to start radiation I realized an area I thought was scar tissue was a lump. Needle biopsy confirmed it is a recurrence. We followed w/ a PETCT and MRI which showed a small area on my right illiac crest, approx. 18 x 13 mm in size, confirmed by biopsy to be TNBC. I have sought out 2nd opinions and all believe that receiving Sacituzumab (an immunccojugate) is my best option. Given I am ogliometastatic my goal is to reduce the primary recurrence with chemo, have surgery to remove the entire area and then radiate the bone met. Given my track record with chemo I am nervous of resistance. FENBENDAZOLE / MEBENDAZOLE was recommended to me and I have shared it with my doctors - one of which is very intrigued and looking more into it. I would like have on deck a protocol for myself to take this, if the chemo route seems to be failing. Could you advise on:
 
Dosage - I am 5'2" - 117 lbs with a very fast metabolism 
Chemo Interactions - is it safe to take while on chemo drugs? Because the Sacituzumab is a trial drug I am hesitant to take anything else with it. 
 
Currently reading through all the other helpful information on this site. Thank you so much for your dedication. Really hope to hear from you soon.
 
Best,
Kati  
 
 
 
 

Quote
Daniel
(@daniel)
New Member Admin
Joined: 4 years ago
Posts: 398
10/09/2019 9:06 pm  

@kati1983

Dear Kati,

I am so sorry you have to go through this at this age. I hope you will be better and better soon.

I have two (long) answers for you. First will be more specific and will post it as part of this msg, and the next one is more general, a comment that I responded to someone else on breast cancer but it will be helpful to you too.

Regarding your question, as I understand Sacituzumab is a targeted chemo (metabolite of Irinotecan) https://en.wikipedia.org/wiki/Sacituzumab_govitecan. As a rule, I would stop anything that could slow down cancer cells, 3 days prior to chemo. Using Fenbendazole after that or before but stop 3 days prior to chemo should help and should not have any negative interference in my view, based on the mechanisms I am aware of. The dose used by Joe and discussed in the post I wrote on Fenbendazole should be suitable regardless of the weight.

In addition, when dealing with TNBC, here is what I would consider the following:

If surgery is planned, I would consider the following:

  1. Using Chloroquine at 500mg/week (that means ~2 capsules/week) for 4 weeks will reduce the chance of metastatsis due to surgery 

Reference: Preventing invasive breast neoplasia with chloroquine  https://cancerres.aacrjournals.org/content/77/13_Supplement/CT140  

  1. Using Ketorolac prior to surgery is known to reduce cancer recurrence. It is important to discuss that with the surgeon. Watch this video  https://www.youtube.com/watch?v=H8zVrYEW8vE&feature=youtu.be

Reference 1: Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index  https://www.ncbi.nlm.nih.gov/pubmed/29718396

Reference 2: Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery  https://www.ncbi.nlm.nih.gov/pubmed/24464611  

Reference 3: Presented by Dr. Vikas P. Sukhatme: A Simple, One-Time, Inexpensive and Non-Toxic Intervention to Improve Cancer Survival  https://www.youtube.com/watch?v=H8zVrYEW8vE&feature=youtu.be  

To possibly improve the current treatment I would consider one of the following approaches:

  1. A light combo of repurposed drugs and supplements:

Repurpused drugs:

- Metformin 1000mg/day (starting first week with 500mg/day and moving up to 1000mg/day after one week)

- Atorvastatin 80mg/day (starting with 40mg/day and moving up to 80mg/day after two weeks)

- Mbendazole 200mg/day or Fenbendazole as discussed here  https://www.cancertreatmentsresearch.com/fenbendazole/

Supplements:

- Omega 3, minimum 3g/day - if the one from fish is not good you can also find the one produced from other sources

- HCA 1500mg/day

- Lycopene 120mg/day

- Quercetin 2g/day

- Vitamin D3 5000ui/day

- Milk Thilste 500mg/day

- Boswellia serrata 3000 mg/day

All should be stop 2-3 days before chemo and restarted with chemo, step by step. If surgery, Omega 3 has to be stopped due to blood thinning effects.

  1. A more intensive combo of repurposed drugs and supplements:

Repurpused drugs:

- Metformin 1000mg/day (starting first week with 500mg/day and moving up to 1000mg/day after one week)

- Atorvastatin 80mg/day (starting with 40mg/day and moving up to 80mg/day after two weeks) - a even better statin is discussed here  https://www.cancertreatmentsresearch.com/cholesterol-lowering-statin-drugs-to-fight-cancer/

- Mbendazole 200mg/day and/or Fenbendazole as discussed here  https://www.cancertreatmentsresearch.com/fenbendazole/

- Doxycicline 100mg/day

- Auranofin 3mg/day and after two weeks 3mg 2x/day as used in CUSP protocol  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226667/

- Propanolol - the dose is discussed here but it has to be verified with the medical doctor if heart status allows to be taken  https://www.cancertreatmentsresearch.com/propranolol-hexokinase-2-inhibiton-a-similar-anticancer-mechanism-as-that-of-3-bromopyruvate-3bp/

Supplements:

- Omega 3, minimum 3g/day - if the one from fish is not good you can also find the one produced from other sources

- HCA 1500mg/day

- Lycopene 120mg/day

- Quercetin 2g/day

- Vitamin D3 5000ui/day

- Milk Thilste 500mg/day

- Probiotics

- Boswellia serrata 3000 mg/day

All should be stop 2-3 days before chemo and restarted with chemo, step by step. If surgery, Omega 3 has to be stopped due to blood thinning effects.

Other points:

Bisphosphonate - may help to reduce the chance for bone mets - did the oncologist implemented that? Other intravenous treatments such as 2DG metronomic could be discussed separately.

You may also want to check with the oncologist the possibility of using the following 3 drugs:

Bicalutamide

Here is a case of a heavily pretreated woman with metastatic TNBC and AR expression who achieved a complete clinical response after 4 months of treatment with the AR antagonist bicalutamide.

According to this article and case report, complete response could be obtained in some triple negative breast cancers when the patinet is treated with a common drug used for prostate cancer called Bicalutamide. Bicalutamide is a androgen receptor antagonist and it seems that 10% to 32% of the triple negative breast cancers have androgen receptors that can be targeted by Bicatulamide.

Reference: Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature  http://ascopubs.org/doi/full/10.1200/jco.2013.49.8899

Estradiol

Another form of estrogen receptor — called estrogen beta — is present in 25 percent of triple-negative tumors, as well as in over 30 percent of estrogen receptor-positive breast cancer tumors. Research showed that the estrogen receptor beta is a tumor suppressor, which correlates with better patient outcomes.

"Remarkably," claims Hawse, "we discovered that estradiol, which normally stimulates [the] growth of cancer cells in tumors that express estrogen receptor alpha, has the opposite effect in triple-negative breast cancer."  https://www.medicalnewstoday.com/articles/323281.php

Here is the research paper demonstrating the anti-cancer effects of Estradiol: ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.  https://www.ncbi.nlm.nih.gov/pubmed/30257941

Mayo researchers identify potential new treatment for subset of women with triple-negative breast cancer  https://newsnetwork.mayoclinic.org/discussion/mayo-researchers-identify-potential-new-treatment-for-subset-of-women-with-triple-negative-breast-cancer/

Clofazimine

Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor  https://www.ncbi.nlm.nih.gov/pubmed/30771433  Wnt signaling is overactivated in triple-negative breast cancer (TNBC) and several other cancers, and its suppression emerges as an effective anticancer treatment. However, no drugs targeting the Wnt pathway exist on the market nor in advanced clinical trials. Here we provide a comprehensive body of preclinical evidence that an anti-leprotic drug clofazimine is effective against TNBC. Clofazimine specifically inhibits canonical Wnt signaling in a panel of TNBC cells in vitro. In several mouse xenograft models of TNBC, clofazimine efficiently suppresses tumor growth, correlating with in vivo inhibition of the Wnt pathway in the tumors. Clofazimine is well compatible with doxorubicin, exerting additive effects on tumor growth suppression, producing no adverse effects. Its excellent and well-characterized pharmacokinetics profile, lack of serious adverse effects at moderate (yet therapeutically effective) doses, its combinability with cytotoxic therapeutics, and the novel mechanistic mode of action make clofazimine a prime candidate for the repositioning clinical trials. Our work may bring forward the anti-Wnt targeted therapy, desperately needed for thousands of patients currently lacking targeted treatments.

I hope this helps.

Kind regards,
Daniel

 

 


ReplyQuote
Daniel
(@daniel)
New Member Admin
Joined: 4 years ago
Posts: 398
10/09/2019 9:11 pm  

Here is a reply I wrote to someone else sometime ago but it may be relevant to you too:

https://www.cancertreatmentsresearch.com/fenbendazole/#comment-8822


ReplyQuote
Share: